EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
06.08.2008 Bulletin 2008/32

(21) Application number: 01999388.0

(22) Date of filing: 06.12.2001

(51) Int Cl.:
A61K 39/395 (2006.01) A61K 39/385 (2006.01)

(86) International application number:
PCT/CU2001/000012

(87) International publication number:

(54) IMMUNOTHERAPEUTIC COMBINATIONS FOR THE TREATMENT OF TUMORS
IMMUNTHERAPEUTISCHE KOMBINATIONEN ZUR TUMORBEHANDLUNG
COMBINAISONS IMMUNOTHERAPEUTIQUES UTILISEES DANS LE TRAITEMENT DES TUMEURS

(84) Designated Contracting States:
AT BE CH CY DE DK ES FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 08.12.2000 CU 28700

(43) Date of publication of application:
08.10.2003 Bulletin 2003/41

(73) Proprietor: Centro de Inmunologia Molecular
Ciudad Habana 12100 (CU)

(72) Inventors:
• PEREZ RODRIGUEZ, Rolando
  Provincia Ciudad Habana 10500 (CU)
• GONZALEZ MARINELLO, Gisela, Maria
  Provincia Ciudad Habana 11600 (CU)
• CROMBET RAMOS, Tania
  Provincia Ciudad Habana 10800 (CU)
• BEAUSOLEIL DELGADO, Irene
  Playa,
  Provincia Ciudad Habana 12100 (CU)

(74) Representative: Prins, Adrianus Willem et al
Vereenigde
P.O.Box 87930
2508 DH Den Haag (NL)

(56) References cited:
EP-A- 0 657 175

Remarks:
The file contains technical information submitted after
the application was filed and not included in this
specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
The present invention relates to immunology, and especially to cancer immunotherapy; and particularly provides an immunotherapeutic kit for inducing a low growth rate and/or removing tumoral cells.

Prior Art:

The system of the EGF receptor (EGF-R) and its ligands constitutes a molecular complex whose interaction regulates in a specific way cellular growth and its impact has been demonstrated in the uncontrolled growth of tumors of epithelial cell origin. During tumorigenesis the paracrine and autocrine control of EGF-R activation is deregulated, due to growth factor over-production, because of the high rate of synthesis and/or receptor mutations.

The EGFR - ligand system has been the target of passive immunotherapy (PI) using monoclonal antibodies (Mab) against EGF-R, in native form, associated with drugs, toxins, or radioactive isotopes (Vollmar AM et al. (1987) J Cell Physiol 131:418-425) in tumors with high expression of this receptor. These antibodies have been selected by their capacity to inhibit the binding of EGF to its receptor (neutralizing antibodies). Several clinical trials with Mabs are being carried out and some have shown promising results as it is the case of Phase II clinical trials with the Mab C225 in breast, pancreatic and renal cancer, in addition to Phase III trials in head and neck cancer (Mendelsohn, J et al. (1999) J Natl Cancer Inst 91:91-100). While the role of EGFR and its ligands in tumor growth is not yet known, there are suggestions that EGF-R expression in tumor cells induces a mechanism for autocrine stimulation that leads to uncontrolled proliferation of those cells (Schlessinger J et al. 1983) that drives cellular growth and differentiation. Overexpression of the receptor occurs in some types of cancers, mainly of epithelial origin, which has been a target for cancer immunotherapy. Such is the case for breast, bladder, ovary, uterine, colon, lung, brain, prostate and head and neck tumors. EGF-R expression has proven to be an indication of bad prognosis in breast cancer (Perez R et al. (1984) Breast Cancer and Treatment 4:189-193). The role of EGFR and its ligands in tumor growth is not yet known, there are suggestions that EGF-R expression in tumor cells induces a mechanism for autocrine stimulation that leads to uncontrolled proliferation of those cells (Schlessinger J et al. (1983) Crit Rev Biochem 14 (2):93-111).

The main ligands of this system are the Epidermal Growth Factor (EGF) and the Transforming Growth Factor alpha type (TGFalpha). There are other ligands belonging to the EGF superfamily, like: amphireguline (AR), crypto-1 (CR1), Heparin Growth Factor, betacellulin, epiregulin, and others.

EGF is a 53 amino acid polypeptide with a molecular weight of 6045Da, which is mitogenic for cells of epithelial origin. Its action is mainly paracrine through its binding to EGF-R.

TGF alpha is a 50 amino acid polypeptide able to compete with EGF for binding to EGF-R. Anti-EGF antibodies are not able to recognize TGF alpha (Todaro G J et al. (1976), Nature 264:203-212) that drives cellular growth and differentiation. Overexpression of the receptor occurs in some types of cancers, mainly of epithelial origin, which has been a target for cancer immunotherapy. Such is the case for breast, bladder, ovary, uterine, colon, lung, brain, prostate and head and neck tumors. EGF-R expression has proven to be an indication of bad prognosis in breast cancer (Perez R et al. (1984) Breast Cancer and Treatment 4:189-193). The role of EGFR and its ligands in tumor growth is not yet known, there are suggestions that EGF-R expression in tumor cells induces a mechanism for autocrine stimulation that leads to uncontrolled proliferation of those cells (Schlessinger J et al. (1983) Crit Rev Biochem 14 (2):93-111).

The EGFR - ligand system has been the target of passive immunotherapy (PI) using monoclonal antibodies (Mab) against EGF-R, in native form, associated with drugs, toxins, or radioactive isotopes (Vollmar AM et al. (1987) J Cell Physiol 131:418-425) in tumors with high expression of this receptor. These antibodies have been selected by their capacity to inhibit the binding of EGF to its receptor (neutralizing antibodies). Several clinical trials with Mabs are being carried out and some have shown promising results as it is the case of Phase II clinical trials with the Mab C225 in breast, pancreatic and renal cancer, in addition to Phase III trials in head and neck cancer (Mendelsohn, J et al. (1999) American Society of Clinical Oncology Meeting). Other Phase II clinical trials showing good results have been carried out with the Mab IOR-R3 in lung tumors (Crombet T et al. (2000) Cancer Biotherapy and Biopharmaceutical, manuscript accepted for publication).

Passive immunotherapy with the IOR-R3 Mab (EP586002B1), specific against the EGF-R, has demonstrated that the specific binding of the IOR-R3 to the receptor inhibits EGF/EGF-R binding, with subsequent inhibition of EGFR autophosphorylation. In turn, passive immunotherapy with IOR-R3 inhibited the growth of human tumor cells in nude mice, and it has reduced the rate of tumour growth in some patients in clinical trials. This system has also been target of specific active cancer immunotherapy. One example is the use of a vaccine composed one of the main ligands of EGF-R, EGF, coupled to a carrier protein (US 5,894,018). This vaccine is able to induce a specific antibody response against autologus EGF, to inhibit EGF/EGF-R binding, thus blocking proliferation mechanisms induced by this binding. Preclinical studies have shown that mice immunized with autologous EGF coupled to a carrier protein and administered with a useful adjuvant, increases survival of mice transplanted with Ehrlich Ascitic Tumor (EAT) cells (González G et al. (1996), Vaccine Research 5(4):233-243; González G et al (1997) Vaccine Research 6(2):91-100).

Results from a Phase I clinical trial have been reported for a vaccine containing human recombinant EGF, demonstrating the immunogenicity and safety of vaccination (González G et al (1998), Annals of Oncology 9:1-5).

Disclosure of the Invention:

The present invention intends the use of combined immunotherapies, directed against the receptors with tyrosine...
kinase activity (RTK) and against their ligands, in order to potentiate the effect observed when applying in an independent way the different immunotherapies forms described in the state of the art, directed against only one of the components of the receptor/ligand system. This potentiation is justified for the combined blockade of both, ligands and receptor, in a treatment method that includes both active principles.

[0012] Particularly the invention refers to an immunotherapeutic kit for the treatment of tumors whose effect is on cells whose growth is dependent of the system of receptors with tyrosine kinase activity, characterized in that it comprises the components A, B, C and D, which are used simultaneous or sequentially in the combinations of A + C; or A + D; or B + C; or B + D. wherein A, B, C and D are:

A. - An antibody against a receptor RTK;
B. - An antibody against the ligand(s) of the receptor RTK;
C. - A vaccine comprising a receptor RTK, which induces antibodies against said receptor RTK;
D. - A vaccine comprising the ligand(s) of a receptor RTK, which induces antibodies against said ligand(s);

[0013] In a preferred embodiment of the invention, the monoclonal antibody against the receptor RTK is an antibody against the receptor of the Epidermal Growth Factor, R-EGF, and more specifically it is the antibody humanized against the EGF-R, the hR3, deposited with access number 951110101 in ECACC, England.

[0014] In another embodiment of the invention the antibody against the ligand of the receptor RTK can be an antibody against the EGF or against the TGF alpha.

[0015] Also the invention refers to an immunotherapeutic kit which comprises a vaccine containing as active principle the EGF-R, EGF, TGF alpha, or a conjugated of these molecules with the protein p64K of Neisseria meningitis.

[0016] The immunotherapeutic kit of the instant invention in the combinations proposed inhibits growth of tumor cells to eliminate those cells, based on the blockade of RTK receptors and its ligands. This blockade can be achieved, among other approaches, using combination, simultaneous or sequential, of active immunotherapies (therapeutic vaccines) and passive immunotherapies (Mab) directed to growth factors (i.e.EGF, TGFa) and its receptors (i.e.EGF-R).

[0017] The blockade of growth factors or of their receptors causes inhibition of cellular proliferation. In this invention we show that simultaneous blockade of ligands and/or receptors potentiate the inhibition effect on cellular proliferation. This therapeutic concept is of great importance for treatment of malignant tumors, which are fundamentally caused by an increase in the rate of cellular proliferation.

[0018] Immunotherapeutic combinations of the components of the kit described cause the blockade of RTK receptors and/or their ligands, by means of active and passive immunotherapeutical combinations.

[0019] The referred procedures can be applied to patients with tumors of epithelial origin that over-express EGF-R, in different clinical stages.

[0020] The combination of active and passive immunotherapy can be simultaneous or sequential, independent of the therapeutic procedure used in patients with advanced disease, or as adjuvant therapy.

[0021] In cases of advanced disease, the proposed therapeutic combination is passive immunotherapy with Mab that recognizes the RTK receptor and/or Mab that recognizes ligands of this receptor, in combination with an onco-specific therapy of choice, as first line therapy, followed by active immunotherapy using vaccines directed against the ligands of the receptor and/or to the receptor, to maintain the therapeutic effect.

[0022] In cases of adjuvant therapy the proposed therapeutical combinations are; passive immunotherapy with Mab that recognize either, the RTK receptor and/or its ligands with active immunotherapy using vaccines directed to the receptor’s ligands or to the receptor itself. Or passive immunotherapy with Mab that recognize either, the RTK receptor or its ligands as attack therapy, followed by active immunotherapy with vaccines directed to the receptor’s ligands or to the receptor itself, as maintenance treatment.

[0023] The way to use the kit of the invention is explained in the procedures presented below.

**PROCEDURE 1:** Therapeutic combination including passive immunotherapy with Mab that recognize the RTK receptor (i.e. EGF-R) and/or the receptor’s ligands (i.e. EGF, TGF alpha), followed by active therapy with vaccines directed to the receptor and/or its ligands, to be applied in patients with advanced stage epithelial tumors.

[0024] This is administered to patients with advanced cancer who are not eligible for any other onco-specific therapy.

[0025] The first treatment step will be passive immunotherapy with Mab that recognizes the RTK receptor (i.e. EGF-R), with the property of inhibiting this receptor and/or Mab that recognize the receptors ligands (i.e. EGF, TGF alpha). This will be an acute therapy aimed at the goal of tumor remission, and can be used together with the established onco-specific treatment for this stage of disease.

[0026] This will be followed by active immunotherapy using vaccines that induce receptor blocking antibodies (i.e. anti-EGF-R) and/or ligand blocking antibodies (i.e. anti-EGF, anti-TGF alpha), with the objective of maintaining disease stabilization for longer periods, to avoid new metastases.
The procedure consists of administration to patients in advanced stages of tumors of epithelial origin, of between 4 and 20 doses, ranging between 100 and 400 mg of a Mab that recognizes and inhibits EGF-R, and/or MAb that recognizes the receptor’s ligands. The time between doses will be between 6 to 10 days. The complete treatment can last between 1 to 24 months, concomitant with the established onco-specific therapy. The treatment will continue up to partial or complete tumor regression or up to the point where an adverse reaction occurs that requires treatment cessation.

Between 1 and 4 weeks after this treatment, immunization schedules will be initiated with vaccines directed against EGF-R or its ligands (i.e. EGF, TGFalpha) coupled to a carrier protein (i.e. P64K Neisseria meningitides recombinant protein) and administered in an adequate adjuvant which could be alum (between 1 and 2 mg/dose) or Montanide ISA 51 (between 0.6 and 1.2 mL/dose). Each dose contains between 50 and 800 µg of active ingredient (receptor or ligand) coupled to the carrier protein, in a final volume of between 0.6 and 5 mL. The immunization schedule is 5 to 8 initial immunizations for response induction, given every 7 to 15 days. Immunizations can be preceded by administration of cyclophosphamide, between 100 and 500 mg/m² of body weight, administered 2 to 4 days before the 1st immunization. Vaccines can be formulated in any other vaccine vehicle (i.e. liposomes, DNA vaccines, viral vectors).

Vaccines can be formulated as independent products or as a unique vaccine formulation.

In this period, blood will be extracted from patients in order to measure biochemical blood markers and specific antibody titers against the ligand or receptor to which the vaccine is directed. Extractions will be done weekly or monthly.

Subsequently, re-immunizations will be done if antibody titers decrease, every 1 to 3 months for a period of 1 to 2 years.

**PROCEDURE 2:** Immunotherapeutic combination including passive immunotherapy with Mab that recognizes a RTK receptor (i.e. EGF-R) and/or its ligands (i.e. EGF, TGF alpha) together with active immunotherapy with vaccines directed against the receptor and/or its ligands, as adjuvant treatment.

Passive treatment with Mab recognizing a RTK receptor (i.e. EGF-R) inhibiting its activity and/or Mab recognizing receptor’s ligands (i.e. EGF, TGF alpha), together with an active treatment with vaccines that induces an antibody response that blocks the receptor and/or its ligands, will be administered to patients immediately after diagnosis and/or surgical treatment.

Those treatments, administered together, will have a synergistic effect, enabling a higher percentage of regression and/or clinical disease stabilization.

Patients with tumors of epithelial origin are amenable to this treatment, that consists of between 4 to 20 doses, ranging between 100 and 400 mg, of Mab recognizing and inhibiting RTK receptors and/or it ligands. The time between doses will be between 6 to 10 days and the treatment can last between 1 to 24 months. The treatment will continue until partial or complete tumor regression or up to the point where an adverse reaction occurs that requires treatment cessation.

**PROCEDURE 3:**

Immunotherapeutic combination including passive immunotherapy with Mal recognizing RTK receptors (i.e. EGF-R) and/or its ligands (i.e. EGF, TGF alpha), followed by active immunotherapy with vaccines directed against the receptor and/or it ligands, to be applied as adjuvant therapy.

This will be applied to patients immediately after diagnosis and/or surgical treatment.

The goal of this treatment is to use acute therapy to obtain tumor remission, via initial passive immunotherapy with Mab recognizing and inhibiting RTK receptors (i.e. EGF-R) and/or Mab recognizing its ligands (i.e. EGF, TGF alpha). Subsequently, active immunotherapy will be initiated using vaccines inducing blocking antibodies against the receptor (i.e. EGF-R) or it ligands (i.e. EGF, TGF alpha). The aim of the 2nd treatment is to obtain a longer period of freedom from disease, to avoid the appearance of new metastases.

The procedure consists of administration to patients at advanced stages of cancer of epithelial origin, from 4 to 20 doses of between 100 and 400 mg of Mab that recognizes and inhibits the EGF-R and/or its ligands. The time between doses will be between 6 to 10 days and the treatment duration can be between 1 to 24 months. The treatment will continue until partial or complete tumor regression, or until any adverse reaction occurs that requires treatment cessation.

Between 1 to 4 weeks after the end of treatment, immunization schedules will begin with vaccines directed against the EGF-R or some EGF-R ligand (i.e. EGF, TGF alpha), according to the schedule described in procedure #1.
EXAMPLES:

**Example 1: Immunization schedule with EGF vaccine in cancer patients, using alum as adjuvant.**

[0040] With the main goal of demonstrating immunogenicity and safety of EGF, a clinical trial was performed in which 10 patients were immunized with an EGF Vaccine (US 5,894,018), using P64K as carrier protein and alum as adjuvant.

[0041] Patient 1.1 (MMG) was included in the trial with a diagnosis of metastatic epidermoid carcinoma of the lung, with progressive disease, and not eligible for any other onco-specific treatment.

[0042] The patient was immunized following a schedule of 5 initial dose of the vaccine, containing 50ug of EGF and 2 mg alum, administered on days 1, 7, 14, 21 and 51.

[0043] Blood extraction was performed on days 0, 15, 30, 45, 60 and monthly thereafter for blood biochemical measurements and for EGF- specific antibodies.

[0044] Antibody titers were measured by means of an ELISA test, antibody titers being determined as the maximal sera dilution that gives a positive result in the ELISA test. (O.D values equal or higher 2 times the blank).

[0045] Re-immunization was performed using the same vaccine dose when a decrease in antibody titers was detected.

[0046] Patient MMG developed an anti-EGF antibody response with maximum titers up to 1:8000.

[0047] The kinetics of the antibody response is shown in figure 1.

[0048] After the beginning of the vaccination schedule the patient showed clinical and radiological stabilization of disease for 15 months. The patient died 23.2 months after the first vaccination.

**Example 2: Immunization schedule with EGF vaccine in cancer patients, using Montanide ISA 51 as adjuvant.**

[0049] With the main goal of demonstrating immunogenicity and safety of EGF using P64K as a carrier protein and Montanide ISA 51 as an adjuvant, a clinical trial was performed in which 10 patients were immunized.

[0050] Patient 2.1 (AMG) was included in the trial with a diagnosis of epidermoid carcinoma of the lung, with progressive disease, being ineligible for any other onco-specific treatment.

[0051] The patient was immunized according to a schedule of 5 initial doses of the vaccine containing 50ug of EGF in 0.6 mL total volume, emulsified with 0.6 mL of Montanide ISA 51 immediately before use, and administered on days 1, 7, 14, 21 and 51.

[0052] Blood extractions were performed on days 0, 15, 30, 45, 60 and monthly thereafter for blood biochemical measurements and measurement of specific anti-EGF antibodies.

[0053] The antibody titers were measured by means of an ELISA test, antibody titers being determined as the maximal sera dilution that gives a positive result in the ELISA test. (O.D values equal or higher 2 times the blank).

[0054] Re-immunization was performed using the same vaccine dose when a decrease in antibody titers was detected.

[0055] Patient AMG developed an anti-EGF antibody response with maximum titers of up to 1:32000, with kinetics of response shown in figure 2.

[0056] After the beginning of the vaccination schedule, the patient showed stabilization of disease for 12months, at which point clinical and radiological tumor regression was diagnosed.

[0057] On the 14th month after the beginning of vaccination, a 2nd primary tumor appeared. The patient died 18 months after inclusion from a surgical complication of this 2nd tumor.

**Example 3: Immunization schedule in cancer patients, with EGF vaccine, using alum as adjuvant and low dose cyclophosphamide pre-treatment.**

[0058] A clinical trial was carried out in which 10 patients were immunized with the main goal of demonstrating immunogenicity and safety of the EGF Vaccine using P64K as carrier protein and alum as adjuvant after cyclophosphamide pre-treatment.

[0059] Patient 3.1, FNR, was included in the trial with a diagnosis of epidermoid carcinoma of the lung, with progressive disease, being ineligible for any other onco-specific treatment.

[0060] The patient was treated with cyclophosphamide (100 mg/m² of body surface), 3 days before the first immunization of the EGF Vaccine. The vaccination schedule was 5 doses of the vaccine composition, containing 50 ug of EGF and 2 mg of alum, administered on days 1, 7, 14, 21 and 51.

[0061] Blood extractions were performed on days 0, 15, 30, 45, 60 and then monthly for blood chemistry and specific anti-EGF antibody determinations.

[0062] Antibody titers were measured by means of an ELISA test, antibody titers being determined as the maximal sera dilution that gives a positive result in the ELISA test. (O.D values equal or higher 2 times the blank).

[0063] Re-immunization was performed using the same vaccine dose, when a decrease in antibody titers was detected.

[0064] The patient developed an anti-EGF antibody response with maximum titers up to 1.8000, as shown in figure 4.
After the beginning of the vaccination schedule, the patient showed disease stabilization for 19 months.

Example 4: Immunization schedule with EGF vaccine in cancer patients, using Montanide ISA 51 as adjuvant and cyclophosphamide pre-treatment.

A clinical trial was carried out in which 10 patients were immunized with the main goal of demonstrating immunogenicity and safety of the EGF Vaccine, using P64K as carrier protein and and Montanide ISA 51 as adjuvant after low-dose cyclophosphamide pre-treatment. Patient 4.1, JPG, was included in the trial with a diagnosis of non-small cell lung adenocarcinoma, being ineligible for any other onco-specific treatment.

The patient was treated with cyclophosphamide (100 mg/kg of body weight), 3 days before the first immunization of the EGF Vaccine. The vaccination schedule was 5 doses of the vaccine composition, containing 50 ug of EGF in 0.6 mL total volume, emulsified with 0.6 mL of Montanide ISA 51 immediately before use, administered on days 1, 7, 14, 21 and 51.

Blood extractions were performed on days 0, 15, 30, 45, 60 and then monthly for blood chemistry and specific anti-EGF antibody determinations.

Antibody titers were measured by means of an ELISA test, antibody titers being determined as the maximal sera dilution that gives a positive result in the ELISA test. (O.D values equal or higher 2 times the blank).

Re-immunization was performed, using the same vaccine dose, when a decrease in antibody titers was detected.

Patient JPG developed an anti-EGF antibody response with maximum titers up to 1:400000, as shown in figure 5.

After the beginning of the vaccination schedule the patient showed disease stabilization for 6 months.

Example 5: Immunogenicity of EGF vaccination and its relationship to disease stabilization in patients with cancer.

In a Phase I trial, 10 patients at stages III or IV of Non Small Cell Lung cancer (NSCLC), were treated with 5 initial doses of vaccine composition containing 50ug of EGF and 2 mg of alum, administered on days 1, 7, 14, 21 and 51.

The other 10 patients (NSCLC, stages III or IV), were immunized with 5 doses of the vaccine composition containing 50 ug of EGF, in a total volume of 0.6 mis, emulsified with the same volume (0.6 mL) of Montanide ISA 51.

Antibody titers were measured by means of an ELISA test, with antibody titers determined as the maximal sera dilution that gives a positive result in the ELISA test. (O.D values equal or higher 2 times the blank).

In this trial, 50% of patients developed an anti-EGF antibody response with antibody titers of 1:4000 or higher (, Good Antibody Responders, GAR group) and 50% antibody titers below 1:4000 (Bad Antibody Responders, BAR group).

In the GAR group, 87.5% of patients showed clinical and radiological disease stabilization for at least3 months after the beginning of treatment.

In the BAR group, only 11.1% of patients showed this stabilization profile (Table 1).

These data demonstrate the relationship between anti-EGF antibody levels and tumor stabilization.

Chart 1: Relationship of antibody responses and clinical and radiological disease stabilization.

<table>
<thead>
<tr>
<th>% of patients</th>
<th>Disease stabilization for at least 3 months after beginning treatment.</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAR 50%</td>
<td>87.5%</td>
</tr>
<tr>
<td>BAR 50%</td>
<td>11.1%</td>
</tr>
</tbody>
</table>

Example 6: Immunogenicity of EGF vaccination and relationship to survival of cancer patient subjected to this treatment.

Forty stage III /IV NSCLC patients were treated, in groups of 10, with the schedules detailed in examples 1,2,3 and 4.

They were characterized as GAR and BAR according to criteria exposed in example 6.

Of the total of patients treated with the previously described schedules, 50% turned out to be GAR and 50% BAR.

When survival patterns were compared between GAR and BAR patients, a statistically significant difference was observed, with a mean survival of 9.1 months for GAR and a mean survival of 4.5 months for BAR (p <0.02). This result is showed in figure 6.
Example 7: Therapeutic effect of the combination of Radiotherapy and Mab IOR-R3:

[0085] Patient RML, diagnosed with stage IV tongue base epidermoid carcinoma, was included in the clinical trial using the combination of radiotherapy (RTP) and IOR-R3. The patient received 200 mg of Mab once a week for 6 weeks. The accumulated dose of Mab was 1200 mg and the total radiation dose was 60 Gy.

[0086] When the combination therapy was complete the patient showed complete remission of the primary tumor and its metastases (figure 7). This response was maintained for more than 13 months.

Example 8: Therapeutic effect of the combination of Radiotherapy and Mab IOR-R3:

[0087] Patient EPG, diagnosed with stage III tonsil epidermoid carcinoma with cervical adenopathies, was included in the clinical trial using the combination of radiotherapy (RTP) and IOR-R3. The patient received 200 mg of Mab once a week for 6 weeks and a total radiation dose of 64 Gy.

[0088] After treatment, this patient showed complete remission of the tumor lesion (figure 8). The response was maintained for more than 13 months.

Example 9: Therapeutic effect of the combination of Radiotherapy and Mab IOR-R3:

[0089] Patient CHA, diagnosed with stage IV tonsil tumor, with bilateral cervical adenopathies, was included in the clinical trial using a combination of radiotherapy (RTP) and IOR-R3. The patient received 400 mg of Mab once a week for 6 weeks, for an accumulated dose of 2400 mg. Concomitantly, the patient received a total radiation dose of 64 Gy.

[0090] When concluding the treatment this patient was in complete remission of the primary tumor and the loco-regional metastasis (figure 9). The response was maintained for 12 months.

Example 10: Schedule of combined Mab IOR-R3 / EGF vaccine treatments in patients with advanced stage tumors:

[0091] Patient ARP, diagnosed with epidermoid carcinoma of the head and neck, received sequential treatment of Mab IOR-R3 and EGF Vaccine.

[0092] The patient received 200 mg of Mab once a week for 6 weeks, in combination with a total of 30 doses of radiotherapy, 5 doses per week for 6 weeks, for an accumulated radiation dose of 60 Gy.

[0093] After treatment, this patient was in complete remission of the primary tumor. An immunization schedule with the EGF Vaccine began one month after conclusion of the treatment with the Mab. The patient received 5 doses of 50 ug of EGF conjugated to protein P64k, in a total volume of 0.6 ml, emulsified with 0.6 ml of Montanide ISA 51 immediately before use. The immunizations were carried out on days 1, 7, 14, 21 and 51.

[0094] The patient remains in the follow-up period.

Example 11: Schedule of combined Mab IOR-R3 / EGF vaccine treatments in patients with advanced stages tumors:

[0095] Patient MRM, diagnosed with epidermoid carcinoma of the lung, was subjected to surgical intervention. One month after the surgery the patient began a combined treatment of passive immunotherapy with Mab IOR-R3 concomitantly with the EGF vaccine.

[0096] Figure 10 details the schedule of dose intervals. The patient is in follow up.

BRIEF DESCRIPTION OF FIGURES:

[0097] Figure 1: Kinetics of anti-EGF antibody response in patient MMG, immunized as detailed in example 1. Arrows indicate times of re-immunizations.

Figure 2: Kinetics of anti-EGF antibody response in patient AMC, immunized as detailed in example 2. Arrows indicate times of re-immunizations.

Figure 3: Tumor regression observed in patient AMC. The tumor mass is seen on the left at the start of treatment. On the right of the figure it can be seen that 12 months after the start of treatment the tumor mass disappeared.

Figure 4: Kinetics of anti-EGF antibody response in patient FNR, immunized as detailed in example 3. Arrows indicate times of re-immunizations.

Figure 5: Kinetics of anti-EGF antibody response in patient JPG, immunized as detailed in example 4. Arrows indicate times of re-immunizations.
Figure 6: Kaplan-Maier survival curves of groups of patients with high anti-EGF antibody response (GAR) and with low anti-EGF antibody responses (BAR), as well as that of a historical control group.

[0098] As can be seen, GAR is associated with a significant increase in survival compared with either BAR or with historical controls.

Figure 7: Graphic demonstration of tumor remission in patient RML, treated as detailed in example 7.
Figure 8: Graphic demonstration of tumor regression in patient EPG, treated as detailed in example 8.
Figure 9: Graphic demonstration of the tumor in patient CHA, treated as detailed in example 9.
Figure 10: Combined treatment of Mab IOR-R3 and the EGF Vaccine:

[0099] Arrows above the time axis indicate the day of Mab administration (days 1,7,14,21,28 and 35) and arrows below the time axis indicate the day of immunization with the EGF Vaccine (days 2,8,15,22, and 52).

Claims

1. An immunotherapeutic kit for the treatment of tumor cells whose growth is dependent on a system of receptors with tyrosine kinase activity, characterized in that the kit comprises, for simultaneous or sequential use, the components A + C; or A + D; or B + C; or B + D; wherein
   A is an antibody against the EGF receptor;
   B is an antibody against the ligand(s) of the EGF receptor;
   C is a vaccine comprising the EGF receptor, which induces antibodies against said receptor;
   D is a vaccine comprising the ligand(s) of the EGF receptor, which induces antibodies against said ligand(s).

2. An immunotherapeutic kit according to claim 1, wherein the antibody against the EGF receptor is a humanized antibody.

3. An immunotherapeutic kit according to claim 2, wherein the humanized antibody against the EGF receptor is IOR R3 obtainable from the cell line deposited with ECACC, United Kingdom, under deposit reference 951110101.

4. An immunotherapeutic kit according to claim 1, wherein the antibody B against the ligand(s) of the EGF receptor is an antibody against EGF.

5. An immunotherapeutic kit according to claim 1, wherein the antibody B against the ligand(s) of the EGF receptor is an antibody against TGF alpha.

6. An immunotherapeutic kit according to claim 1, wherein the vaccine C comprises the EGF receptor as active principle.

7. An immunotherapeutic kit according to claims 1, wherein the vaccine D comprises the EGF as active principle.

8. An immunotherapeutic kit according to claim 7, wherein the vaccine comprises as immunogen a conjugate of EGF and P64K protein from Neisseria meningitidis.

9. An immunotherapeutic kit according to claim 1, wherein the vaccine D comprises TGF alpha as active principle.

10. An immunotherapeutic kit according to claim 9, wherein the vaccine comprises as an immunogen a conjugate of TGF alpha and P64K protein from Neisseria meningitidis.

11. Use of a component A, B, C or D, as defined in any one of claims 1-10, for manufacturing a pharmaceutical composition for the treatment of tumor cells whose growth is dependent of a system of receptors with tyrosine kinase activity being the EGF receptor, by simultaneous or sequential administration of the components A + C; or A+D; or B+C; or B+D

Patentansprüche

1. Immuntherapeutische Ausrüstung für die Behandlung von Tumorzellen, deren Wachstum von einem System von
Rezeptoren mit Tyrosin-Kinase-Aktivität abhängt, dadurch gekennzeichnet, dass die Ausrüstung für die gleichzeitige oder aufeinanderfolgende Verwendung die Komponenten A + C oder A + D oder B + C oder B + D umfasst, wobei bedeuten

A einen Antikörper für den EGF-Rezeptor,
B einen Antikörper für den (die) Liganden des EGF-Rezeptors,
C einen Impfstoff, umfassend den EGF-Rezeptor, der den Antikörper für diesen Rezeptor induziert,
D einen Impfstoff, umfassend den (die) Liganden des EGF-Rezeptors, der Antikörper für diesen (diese) Liganden induziert.

2. Immuntherapeutische Ausrüstung nach Anspruch 1, wobei der Antikörper für den EGF-Rezeptor ein humanisierter Antikörper ist.

3. Immuntherapeutische Ausrüstung nach Anspruch 2, wobei der humanisierte Antikörper für den EGF-Rezeptor IOR R3 ist, der von der unter der Hinterlegungsnummer 951110101 beim ECACC, Großbritannien, hinterlegten Zelllinie erhalten werden kann.

4. Immuntherapeutische Ausrüstung nach Anspruch 1, wobei der Antikörper B für den (die) Liganden des EGF-Rezeptors ein Antikörper für EGF ist.

5. Immuntherapeutische Ausrüstung nach Anspruch 1, wobei der Antikörper B für den (die) Liganden des EGF-Rezeptors ein Antikörper für TGF-α ist.

6. Immuntherapeutische Ausrüstung nach Anspruch 1, wobei der Impfstoff C den EGF-Rezeptor als aktiven Grundbestandteil umfasst.

7. Immuntherapeutische Ausrüstung nach Anspruch 1, wobei der Impfstoff D den EGF als aktiven Grundbestandteil umfasst.

8. Immuntherapeutische Ausrüstung nach Anspruch 7, wobei der Impfstoff als Immunogen ein Konjugat von EGF und dem Protein P64K von Neisseria meningitidis umfasst.

9. Immuntherapeutische Ausrüstung nach Anspruch 1, wobei der Impfstoff D TGF-α als aktiven Grundbestandteil umfasst.

10. Immuntherapeutische Ausrüstung nach Anspruch 9, wobei der Impfstoff als ein Immunogen ein Konjugat von TGF-α und dem Protein P64K von Neisseria meningitidis umfasst.


Revendications

1. Trousse immunothérapeutique destinée au traitement de cellules tumorales dont la croissance est dépendante d’un système de récepteurs ayant une activité tyrosine kinase, caractérisée en ce que la trousse comprend, pour une utilisation simultanée ou séquentielle, les composants A+C; ou A+D; ou B+C; ou B+D; dans laquelle

A est un anticorps dirigé contre le récepteur de l’EGF ;
B est un anticorps dirigé contre le(s) ligand(s) du récepteur de l’EGF ;
C est un vaccin comprenant le récepteur de l’EGF, lequel induit des anticorps dirigés contre le(s) récepteur ;
D est un vaccin comprenant le(s) ligand(s) du récepteur de l’EGF, lequel induit des anticorps dirigés contre le(s) ligand(s).

2. Trousse immunothérapeutique selon la revendication 1, dans laquelle l’anticorps dirigé contre le récepteur de l’EGF
est un anticorps humanisé.

3. Trousse immunothérapeutique selon la revendication 2, dans laquelle l’anticorps humanisé dirigé contre le récepteur de l’EGF est l’IOR R3 pouvant être obtenu à partir de la lignée cellulaire déposée à l’ECACC, Royaume-Uni, sous le numéro de dépôt 951110141.

4. Trousse immunothérapeutique selon la revendication 1, dans laquelle l’anticorps B dirigé contre le(s) ligand(s) du récepteur de l’EGF est un anticorps dirigé contre l’EGF.

5. Trousse immunothérapeutique selon la revendication 1, dans laquelle l’anticorps B dirigé contre le(s) ligand(s) du récepteur de l’EGF est un anticorps dirigé contre le TGF alpha.

6. Trousse immunothérapeutique selon la revendication 1, dans laquelle le vaccin C comprend le récepteur de l’EGF comme principe actif.

7. Trousse immunothérapeutique selon la revendication 1, dans laquelle le vaccin D comprend l’EGF comme principe actif.

8. Trousse immunothérapeutique selon la revendication 7, dans laquelle le vaccin comprend comme immunogène un conjugué d’EGF et de protéine P64K de Neisseria meningitidis.

9. Trousse immunothérapeutique selon la revendication 1, dans laquelle le vaccin D comprend du TGF alpha comme principe actif.

10. Trousse immunothérapeutique selon la revendication 9, dans laquelle le vaccin comprend comme immunogène un conjugué de TGF alpha et de protéine P64K de Neisseria meningitidis.

11. Utilisation d’un composant A, B, C ou D, tel que défini dans l’une quelconque des revendications 1 à 10, pour la fabrication d’une composition pharmaceutique destinée au traitement de cellules tumorales dont la croissance est dépendante d’un système de récepteurs à activité tyrosine kinase, à savoir le récepteur de l’EGF, par administration simultanée ou séquentielle des composants A + C ; ou A + D ; ou B + C ; ou B+D.
Figure 1.

![Patient MMG graph](image)

Figure 2.

![Patient AMG graph](image)
Figure 3.

Figure 4.
Figure 5.

Patient JPG

log sera dilution

0 21 60 120 180 240 300 360 420 480

Time (Days)

Figure 6.

Survival of patients with high and low titters vs EGF (2 trials)

0 5 10 15 20 25

Time (months)

1.0

0.8

0.6

0.4

0.2

0.0

Accumulated survival

- High-Titters
- Low-Titters
- Historical Controls
Figure 7.
Tumor (Tongue Base)  Complete remission

Before  After

Figure 8.
Tumor (Tonsil)  Complete remission
Figure 9.

Before (Tonsil tumor and the cervical node)

After (Complete remission of the primary tumor and the cervical node)
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- EP 586002 B1 [0009]
- US 5894018 A [0009] [0040]

Non-patent literature cited in the description

- ULLRICH TO ; SCHLESSINGER J. Cell, 1990, vol. 61, 203-212 [0004]
- MENDELSON, J et al. American Society of Clinical Oncology Meeting, 1999 [0008]
- CROMBET T et al. Cancer Biotherapy and Biopharmaceutical, 2000 [0008]
- GONZÁLEZ G et al. Vaccine Research, 1997, vol. 6 (2), 91-100 [0009]